Is Teva looking to upscale its R&D activity to new chemical entity (NCE), novel drug delivery systems?
For NCEs, we have a different approach. It was based on Israeli innovation in Israeli academic institutes. We have so far had two proven successes. So the pipeline is there. It’s an evolutionary process. It’s not like we have 10 NCEs. As much as we are number one in generics industry, we are not Pfizer! Are you looking at research collaborations with Indian academic institutions also? We are not excluding it. It is part of our Indian team’s agenda. It’s a part of our basic networking activity and we’ll take it from there. We do appreciate science and medicine but first we have to develop a profound understanding of the place. We are not doing this because it is India or elsewhere, we are doing it in the best interests of Teva. Regent is into API and now this research centre. Would the company also be entering the domestic market? No. It is an API unit. We are not mixing the businesses. We have a shell company called Teva India and, if at all, that company would enter the Indian market.
